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ABSTRACT
Background Digital pathology (DP) has the potential 
to fundamentally change the way that histopathology 
is practised, by streamlining the workflow, increasing 
efficiency, improving diagnostic accuracy and facilitating 
the platform for implementation of artificial intelligence–
based computer- assisted diagnostics. Although the 
barriers to wider adoption of DP have been multifactorial, 
limited evidence of reliability has been a significant 
contributor. A meta- analysis to demonstrate the 
combined accuracy and reliability of DP is still lacking in 
the literature.
Objectives We aimed to review the published 
literature on the diagnostic use of DP and to synthesise 
a statistically pooled evidence on safety and reliability of 
DP for routine diagnosis (primary and secondary) in the 
context of validation process.
Methods A comprehensive literature search was 
conducted through PubMed, Medline, EMBASE, 
Cochrane Library and Google Scholar for studies 
published between 2013 and August 2019. The search 
protocol identified all studies comparing DP with light 
microscopy (LM) reporting for diagnostic purposes, 
predominantly including H&E- stained slides. Random- 
effects meta- analysis was used to pool evidence from the 
studies.
Results Twenty- five studies were deemed eligible to be 
included in the review which examined a total of 10 410 
histology samples (average sample size 176). For overall 
concordance (clinical concordance), the agreement 
percentage was 98.3% (95% CI 97.4 to 98.9) across 24 
studies. A total of 546 major discordances were reported 
across 25 studies. Over half (57%) of these were related 
to assessment of nuclear atypia, grading of dysplasia 
and malignancy. These were followed by challenging 
diagnoses (26%) and identification of small objects 
(16%).
Conclusion The results of this meta- analysis indicate 
equivalent performance of DP in comparison with LM 
for routine diagnosis. Furthermore, the results provide 
valuable information concerning the areas of diagnostic 
discrepancy which may warrant particular attention in 
the transition to DP.
INTRODUCTION
Digital pathology (DP), frequently referred to as 
whole slide imaging (WSI), is a rapidly emerging 
technology.1 2 It has the potential to fundamen-
tally change the way that histopathology is prac-
tised by streamlining the workflow,3 increasing 
efficiency,4 5 improving diagnostic accuracy and 
facilitating the platform for the implementation of 
artificial intelligence–based computer- assisted diag-
nostics.2 Inevitably, these advantages will dictate the 
adoption of this technology which is very likely to 
gather pace rapidly in the next few years.
Currently, only a small number of pathology 
laboratories in the UK and elsewhere are using 
DP for their routine sign- out purposes.6 For more 
widespread adoption of DP in clinical laboratories, 
evidence of safety and reliability is needed, ideally 
in the form of adequately powered multi- site valida-
tion studies, demonstrating equivalent performance 
of DP compared with the existing gold standard of 
light microscopy (LM).7
A number of validation studies have been 
published to date, but most are small single- site 
studies and there is considerable variation in the 
study designs. Previous systematic narrative reviews 
have summarised the qualitative evidence on the 
diagnostic reliability of WSI.8–10 A systematic 
review of 38 validation studies between 1999 and 
2015 reported an overall diagnostic concordance 
ranging from 63% to 100%, with a weighted mean 
of 92.4%.8 That review recognised the limitation 
of small sample size (mean number of cases 140) 
with variable study design and case types. A subse-
quent study based on the systematic review of the 
discordant diagnoses reported 335 discordances 
(4%) among 8069 comparisons of digital and LM 
diagnoses. A significant proportion of those discor-
dances were concerning the diagnosis of dysplasia 
(32%).9 Araújo et al conducted a systematic review 
of studies from 2010 to 2017 reporting intra- 
observer agreement ranging from 87% to 98.3% 
(κ coefficient range 0.8–0.98).10 That review was 
again based on a small selected series of 13 studies 
with a mean sample size of 165. Studies comparing 
the digital diagnosis with either consensus diagnosis 
or original diagnosis by a different pathologist were 
not included in this review.
Since the publication of these reviews, larger 
validation studies have been performed including 
studies supporting regulatory approval and devel-
opment of current recommendations by national 
organisations, providing more guidance and prac-
tical advice on the validation process.11 12
A meta- analysis to demonstrate the combined 
accuracy and reliability of DP is still lacking. In the 
hierarchy of evidence- based healthcare, systematic 
reviews and meta- analysis using statistical methods 
to combine the results of individual studies can 
provide a precise estimate of the effect of size with 
considerably increased statistical power, placing 
them at the apex of the evidence pyramid.
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The aim of this systematic review and meta- analysis was to 
review the quantitative evidence across the validation studies, 
synthesise statistical data and to summarise the evidence on 
safety and reliability of DP.
MATERIALS AND METHODS
Review protocol and registration
This review was conducted in accordance with the guidelines 
by the Preferred Reporting Items for Systematic Review and 
Meta- Analyses (PRISMA).13 The review protocol was regis-
tered with the PROSPERO database (registration number 
CRD42019145977: Centre for Reviews and Dissemination, 
University of York, England), the international prospective 
register of systematic reviews.
Problem statement
To review the existing literature on the diagnostic (primary and 
secondary) use of DP and its comparison with LM in the context 
of the validation process.
 ► Uncover the strength of the concordance evidence between 
DP and LM, in order to highlight the usefulness of transition 
to DP.
 ► To analyse recent evidence on safety and reliability of DP by 
identification of discordant diagnosis on the digital platform.
Definitions
Concordance and discordance
Diagnostic concordance was defined as ‘degree of agreement 
between digital reading and the LM reading for the same sample’. 
Conversely, any difference or variance between the digital and 
LM report would reflect discordance. Intra- observer concor-
dance was the preferred method of evaluation, where possible, 
as per CAP and RCPath guidelines.11 14
Minor and major discordance
Minor discordance reflects a difference between two reports 
which is clinically insignificant and would not affect patient 
management decisions. However, a major discordance leads 
to or can lead to a difference in clinical decision for patient 
management.
Overall concordance
For this review, the overall clinical concordance was also 
recorded, which included concordance as well as minor clini-
cally insignificant discordances.
Search strategy
A literature search was conducted by the primary researcher 
(ASA) through the key electronic databases: PubMed platform 
(National Center for Biotechnology Information, U.S. National 
Library of Medicine, Maryland) including Medline (Medline 
Industries, Illinois, USA), EMBASE (Elsevier, Amsterdam, The 
Netherlands), Cochrane Library (London, England) and Google 
Scholar (Google, California) between 2013 and August 2019. 
To identify any study being currently undertaken, a search of 
ClinicalTrials. gov (U.S. National Institutes of Health, Maryland) 
was performed. A detailed search strategy is available as online 
supplementary content (online supplementary appendix 1).
In order to identify any more potentially eligible articles not 
captured through the aforementioned search, a manual search 
was conducted via forward citation tracking and reference 
search of the included studies.
Article screening and eligibility evaluation
Using Rayyan Qatar Computing Research Institute (QCRI),15 
all results were screened against a predefined eligibility criterion 
(table 1) including full abstract and study title by two indepen-
dent reviewers (ASA and HM).
Studies were included provided they met the full inclusion 
criteria: studies comparing DP with LM reporting for diagnostic 
purposes, predominantly including H&E- stained slides. Studies 
were excluded if they explored applications of DP other than 
diagnosis, predominantly involving ancillary studies or other 
sub- specialist areas.
The screened results were displayed under one of the following 
categories: ‘included’, ‘excluded’ and ‘maybe’. The reasons for 
exclusion were also recorded.
Any disagreements highlighted by Rayyan QCRI between 
the two reviewers were resolved by discussion. Articles in the 
‘maybe’ category were further reviewed by a third reviewer 
(DRJS). Full texts of all potentially eligible articles were retrieved 
and reviewed in detail for further evaluation.
Data extraction
A comprehensive data extraction protocol was developed based 
on the Cochrane Effective Practice and Organization of Care 
template.16 In addition to the generic domains adapted from 
the Cochrane—good practice data collection, domains relevant 
to this review were added. A tailored data record form was 
designed in Microsoft Excel (V.16.38)
Data extraction was conducted by ASA and supported by 
other reviewers (DRJS, HM, IMM, KH, NMR). In case of 
discrepancy between two reviewers, a consensus was reached by 
discussion. For each included article, the following data items 
were extracted: study information, participants, interventions, 
sample, study method, outcome variables and quality assessment 
(box 1). Corresponding authors of the included studies were 
contacted to request any further details, where required.
Quality assessment (QUADAS 2—tailored)
To assess the quality and risk of bias in individual studies, the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS 
2)17 tool was used. QUADAS 2 was tailored according to this 
review’s protocol and some of the signalling questions not 
applicable to the validation studies were excluded. For each 
of the signalling questions, clear and precise instructions were 
produced. For each QUADAS domain, the risk of bias was 
assessed as either ‘low’ or ‘high’ based on the answers to the 
signalling questions. If insufficient information was provided in 
the study, the risk of bias was assessed as ‘unclear’.
Table 1 Inclusion and exclusion criteria for screening of literature 
search results
Inclusion criteria Exclusion criteria
Digital pathology (DP) and light 
microscopy comparison/validation studies
For diagnostic purpose (primary or 
secondary)
Primarily using H&E slides
Studies involving other uses of DP 
including education, research, molecular 
or image analysis
Predominantly involving 
immunocytochemistry, special stains, 
fluorescence or frozen section slides
Cytopathology, autopsy, neuropathology
Not using whole slide images 
(telepathology, robotic or static 
microscopy)
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The quality assessment of all included studies was performed 
by two reviewers. A review specific tailored QUADAS-2 tool is 
available as online supplementary content (online supplemen-
tary appendix 2).
Statistical analysis
For each study, we recorded the number of DP–LM comparisons 
and the number of comparisons where DP and LM diagnoses 
agreed (number of agreements). We considered two definitions 
for agreement (concordance): no difference in clinical manage-
ment (overall concordance) and complete agreement. In three 
studies,18–20 DP–LM comparison for each case was made by 
multiple pathologists with the number of agreements reported 
separately for each pathologist. For those studies, we used the 
average number of agreements for the pathologists.
We considered it reasonable to pool data from all studies but 
accounted for inherent study- specific characteristics by using 
random- effects meta- analysis. We took the number of agree-
ments in a study to have a binomial distribution, with a logit link 
used when modelling the probability of agreement. For studies 
with 100% agreement, 0.5 was added to the agreements and 
disagreements. The ‘meta’21 package in R22 statistical program 
was used to perform the meta- analysis. A forest plot was used to 
summarise the pooled results as well as percentage agreements 
and exact Clopper- Pearson 95% CIs for individual studies.
RESULTS
PRISMA flowchart
Figure 1 shows the PRISMA flowchart summarising the results 
of the review process. The initial systematic search of the 
literature yielded 994 records in total. After removing the dupli-
cate results, abstracts of 828 records were screened for eligibility.
Eligibility screening identified 45 research studies for full- 
text review of these articles of which 25 were deemed eligible 
for inclusion in the review. These studies included a total of 10 
410 histology samples with an average sample size of 176. The 
third reviewer was needed to reach consensus in 8/45 articles. 
One publication incorporated two distinct study phases with 
different samples, analysis and results.23 The two phases of the 
same research paper were recorded separately into the total 
number of included studies. The 25 research papers included 
in the systematic review were based on the evaluation of total 
19 468 LM versus digital comparisons. The quantitative meta- 
analysis included 24 of these studies.
Study demographics
Twenty- three studies had been conducted at single centres (92%) 
and only two (8%) were multi- centre validations. The majority 
of studies (14; 56%) were from America, 10 (40%) from Europe 
and 1 (4%) was from Asia. The majority of these studies (56%, 
n=14) were published from 2015 onward.
Study characteristics: samples, participants, training, washout 
time and equipment
Sample size (figure 2) varied from 6024 to 301725 cases with an 
average of 176 cases. The majority (15; 60%) examined 200 
samples or less with only 3 studies examining 1000 or more 
cases. The largest sample size reported in validation literature 
was 3017 to date.25 Single specialty samples were selected in 
48% (n=12) of the studies, whereas more than one specialty 
samples were included in 52% (n=13) studies (figure 3). None 
of the studies stated the inclusion of cancer screening samples.
The number of pathologists who participated in reporting study 
samples ranged from 1 to 57 with 15 (60%) studies involving 
Box 1 Data collection form with details of domains 
recorded
General Information
Study ID, study title, year of publication, country of origin, single/
multicentre, retrospective/prospective/crossover and journal, 
reference.
Participants
Number of pathologists involved, consultant or trainee level or 
both, and training provided to pathologists.
Interventions
Whole slide imaging scanning system manufacturer/model, 
scanning magnification, resolution of viewing monitor and 
calibration.
Samples
Sample size, total number of slides, total number of readings, 
number of readings per case, total number of reading pairs, 
stains evaluated (H&E, immunohistochemistry (IHC), specials), 
single/multiple specialties included, specialties involved, case 
selection criteria and type of specimen; biopsies/resections/both.
Methodology
Sample enrolment, randomisation, anonymisation, degree of 
blinding, length of washout time, intra-observer/inter- observer, 
provision of clinical details, analysis strategy.
Results
Number of concordant cases, concordance percentage, number 
of discordant cases, discordance percentage, minor discordance, 
major discordance, concordance+minor discordance, 95% CI/
Kappa index, details of discordance, preferred modality, reasons 
for discordance and discordance category.
Figure 1 Flowchart following Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses (PRISMA) guidelines. *Of the 20 
articles excluded, 7 assessed agreement between diagnostic variables 
of a known disease or between broader diagnostic categories, 5 were 
conference abstracts, 3 included irrelevant outcome measures, 2 stated 
insufficient about how samples were analysed, 2 were subset of another 
study and 1 involved cytology cell block preparations.
 o
n
 Septem
ber 23, 2020 by guest. Protected by copyright.
http://jcp.bmj.com/
J Clin Pathol: first published as 10.1136/jclinpath-2020-206764 on 15 September 2020. Downloaded from 
4 Azam AS, et al. J Clin Pathol 2020;0:1–8. doi:10.1136/jclinpath-2020-206764
Review
fewer than 5 pathologists. In one study, 57 pathologists partici-
pated in reporting study samples (n=200) with 28 of them being 
residents/fellows.26 The remaining 23 studies included experi-
enced consultant pathologists while one study did not document 
the experience level of the participating pathologists.
The participating pathologists were provided training for 
using the WSI system before reporting the study samples in 13 
studies (52%). No training was provided in four studies because 
the participants had previous experience with using DP for 
reporting, teaching or tumour boards. Eight studies did not state 
whether training was provided or not.
Clinical information was provided to the reporting patholo-
gists with each case in the majority of the studies (80%, n=20). 
Five studies did not state this.
The length of washout time between DP and LM reporting 
was variable in the included studies and ranged from 2 weeks 
to more than a year (figure 4). Four studies (16%) did not use 
any washout time between the two readings due to the live- 
validation approach.
The whole slide image scanning devices used in the included 
studies comprised seven different scanner manufacturers, Aperio 
(Leica biosystems) being the most commonly used (n=14, 56%). 
Nine studies had performed slide scanning at ×40 magnifica-
tion, eight at ×20, six used a combination of ×20 and ×40, 
and one study used a combination of ×40 and ×60 depending 
on the sample requirement. Viewing monitor resolution was not 
commented on in 10 studies. The details of the scanning systems 
and scan magnification are shown in table 2.
Only five studies performed a prior sample size calculation by 
statistical methods. The sample size for three studies19 25 27 was 
based on non- inferiority tests, but with different non- inferiority 
margins and percentage agreements between DP and LM. Snead 
et al25 collected the baseline multi- disciplinary team meeting 
review data to calculate overall intra- observer and inter- observer 
concordance on ‘LM’ and reached a sample size of just over 
3000 cases.
A summary of main characteristics of included studies is avail-
able online as online supplementary material (online supplemen-
tary appendix 3).
Diagnostic concordance and discordance
The overall concordance was assessed by measuring complete 
agreement along with clinically insignificant variations between 
digital and LM reports. Individual studies percentage agreement 
across 24 studies included in the meta- analysis ranged from 
92.3% to 100%, with the majority (23/24) having percentage 
agreement above 95% and three studies having 100% agreement 
(figure 5). The pooled percentage agreement for overall concor-
dance was 98.3% (95% CI 97.4 to 98.9) across 24 studies. One 
study28 used the kappa coefficient (k=0.81) and did not state the 
concordance percentage. The pooled percentage agreement for 
complete concordance was 92% (95% CI 87.2 to 95.1) (figure 6). 
The studies were heterogeneous (I2=90%, p<0.0001).
The inter- modality (ie, digital and light microscopy) readings 
were performed by the same pathologist in 23 (92%) studies. In 
one study, two- thirds of cases were examined by different pathol-
ogists and one- third by the same pathologist.25 In one study, the 
two modalities were examined by different pathologists.27
A total of 546 major discordances were reported across 
21 studies. Three studies reported only minor differences in 
results.19 29 30 One study28 reported the kappa coefficient and did 
not state the discordance percentage.
Gastrointestinal tract and gynaecological pathology were two 
most commonly reported specialties among the discordant cases, 
followed by skin, breast, genitourinary and renal pathology.
Categorisation of diagnostic discrepancies
Out of 546 major discordances reported across the 25 studies, 
details of diagnosis and preferred modality were provided for 
158 instances. In order to identify and summarise areas of diffi-
culty in the diagnostic performance of WSI, we categorised all the 
major discordances into four main groups based on the under-
lying diagnostic discrepancy. Over half (57%) of the reported 
discordant diagnoses were related to the assessment of nuclear 
atypia, grading of dysplasia and malignancy (group A). These 
Figure 2 Sample size variations across 25 studies.
Figure 3 Illustration of the distribution of specialties/organ systems 
represented across 25 studies (n=number of studies with the inclusion 
of each organ type).
Figure 4 Length of washout period between light microscopy and 
digital pathology readings.
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were followed by challenging diagnoses (26% in group C) and 
identification of small objects (16% in group B). Each category 
was further sub- classified into three to seven sub- classifications 
to capture the nature of discordance. This categorisation was 
based on the findings of this review and previously reported 
reviews.9 10
Within group A, a total of 68 discordant instances concerning 
the grading of epithelial dysplasia and nuclear atypia were 
recorded. The preferred modality for these instances was 
recorded as LM diagnosis (48/68), digital diagnosis (11/68) and 
not clearly stated (9/68). Of those cases, where ground truth was 
LM, the DP under- called (ie, lower grade of dysplasia compared 
with LM) in 30 of 48 (62.5%) and over- called (higher grade of 
dysplasia) in 18 of 48 (37.5%).
Table 3 shows each category with nature of discordance and 
organs/sites involved as well as the percentage of all reported 
major discordances. Figure 7 shows the distribution of four 
groups of discordances across the specialties involved.
The remaining underlying reasons for disagreement were 
stated as follows: difficult case requiring consultation, textural 
quality of amyloid hard to appreciate on a digital display, lack 
of clinical information and non- availability of ancillary stains.
Risk of bias and applicability
The results of quality assessment for risk of bias and applicability 
in individual studies are displayed in table 4. Across the four 
domains (case selection, index test, reference standard, flow and 
timing), the percentage of studies with low risk of bias ranged 
from 75% (20/25) to 92% (23/25), the percentage of studies 
with a high risk of bias ranged from 8% to 25%. An unclear risk 
of bias was found in 12% of the studies. Regarding applicability, 
all studies showed low concern across case selection domain. 
Applicability concern was classed as high across the index test 
domain in one study.
DISCUSSION
This is the first meta- analysis of DP studies and largest systematic 
review to date, based on 25 studies covering 10 412 samples 
and 19 468 glass versus digital comparisons, including from two 
recent multi- centre validation studies.31 32
These studies demonstrated percentage agreement of 98.3% 
(95% CI 97.4 to 98.9) for overall concordance and 92% (95% 
CI 87.2 to 95.1) for complete concordance. This high level of 
agreement across multiple studies provides strong evidence that 
DP is a viable alternative to LM for routine practice and, given 
the multiple additional advantages it offers, can be expected to 
Table 2 Various scanning systems and scanning magnifications used in the included studies
Number of 
studies References
Scanner manufacturers
Aperio Scanner (Leica Biosystems) 14 Al- Janabi et al40, Al- Janabi et al41, Araújo et al42, Arnold et al24, Bauer et al43, Bauer and 
Slaw3, Brunelli et al28, Bucks et al (1)23, Bucks et al (2)23, Hanna et al44, Kent et al45, 
Shah et al46, Williams et al6, Tabata et al31
Ventana (Roche Diagnostics) 5 Campbell et al18, Ordi et al 27, Reyes et al20, Saco et al19, Thrall et al26
Nanozoomer (Hamamatsu) 4 Houghton et al30, Loughrey et al29, Villa et al47, Tabata et al31
Ultra- fast scanner (Philips Intellisite Pathology system) 2 Mukhopadhyay et al32, Araújo et al42
Omnyx VL120 (GE Healthcare) 2 Lee et al48, Snead et al25
Mikroscan vs800 (Olympus Corporation) 1 Tabata et al31
FINO (CLARO, Hirosaki) 1 Tabata et al31
Scanning magnification
×20 9 Al- Janabi et al40, Bauer et al43, Bauer and Slaw3, Al- Janabi et al41, Reyes et al20, Ordi et 
al27, Thrall et al26, Kent et al45, Araújo et al42
×40 8 Houghton et al30, Loughrey et al29, Shah et al46, Saco et al19, Lee et al48, Mukhopadhyay 
et al32, Villa et al47, Hanna et al44
Mix of ×20 and ×40, depending on specimen type 6 Arnold et al24, Campbell et al18, Bucks et al (1)23, Bucks et al (2)23, Tabata et al31, 
Williams et al6
Mix of ×40 and ×60 (0.137 µm/pixel) depending on specimen type 1 Snead et al25
Figure 5 Forest plot representing percentage agreement for overall 
concordance across 24 studies with the number of comparisons, 
participating pathologists and digital pathology training.
Figure 6 Forest plot representing percentage agreement for complete 
concordance across 24 studies.
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replace the LM as the main tool for diagnostic histopathology. 
The studies examined samples from multiple different tissue 
types suggesting the results are fully representative of the breadth 
of diagnostic material encountered in routine practice. However, 
it is noticeable that no studies included ophthalmic samples and 
too few studies examined renal or paediatric samples to enable 
meaningful conclusions to be drawn. None of the studies stated 
which samples, if any, were generated by cancer screening 
programmes, which has been an area of concern in the UK 
National Health Service cancer screening programmes (Public 
Health England personal communication). However, the inclu-
sion of breast, gynaecological and gastrointestinal samples in a 
large proportion of these studies suggest the results should be 
relevant to these sample types.
The 546 discordances were analysed to determine the nature 
of discrepancy and its relevance to patient management. The 
majority (57%) of clinically significant discordances were 
related to grading of dysplasia, atypia and malignancy in various 
tissue types. Grading dysplasia is an important feature which 
relies largely on subjective assessments, and which is a common 
source of discrepancy in histopathology.33–35 The high inci-
dence of discrepancies in this area may in part reflect this diffi-
culty but also indicates grading dysplasia is an important area 
to concentrate on in the transition from LM to DP in order to 
prevent DP introducing an additional error into this challenging 
diagnostic area. Within these discrepancies, however, there was 
no consistent pattern towards over- grading of dysplasia with DP 
as has been suggested in some small studies.36
The second the most common discrepancy (26%) concerned 
challenging diagnoses such as atypical breast lesions (atypical 
ductal hyperplasia, flat epithelial atypia, low- grade ductal carci-
noma in situ), melanocytic lesions, amyloid and small foci of 
invasive malignancy. Difficulty in locating small objects like 
micro- organisms, focal inflammation, granulomata, micrometas-
tasis, mitotic figures and Weddellite calcification were encoun-
tered in 16% of the discordant cases. These discrepancies all 
relate diagnostic areas already known to be contentious and 
where differences of opinion are to be expected33 35 irrespective 
of the modality used to examine the slides.
Some of the diagnostic discrepancies are however likely to be 
related to DP. These include assessment of objects requiring an 
appreciation of textural quality, such as deposits of amyloid, mucin 
and Weddellite calcifications. In these instances, the inability to focus 
through the ‘z’ plane means the observer using DP is unable to detect 
the changes in texture normally visible in LM. Second, the recogni-
tion of small objects, less than 5 µm in size, such as bacteria has been 
identified as area of difficulty on DP. Reproduction of these objects 
in DP systems is clearly inferior to LM because of a combination of 
loss of detail in the image acquisition, restrictions in the scanning 
objective and the reliance of a single focal plane. Finally, any object 
requiring examination under polarised light cannot be adequately 
catered for in the DP systems currently available. Awareness and 
knowledge of these issues is essential if pathologists are to under-
stand the limitations of DP and be able to adapt to its use in their 
own practice safely.
Across this meta- analysis, there are potentially important varia-
tions in study design including sample selection criteria, equipment 
used and length of washout time that could influence the results. 
Where possible, these potential sources of bias have been assessed 
using the QUADAS 2 tool, which demonstrated a low risk of bias 
for the majority of studies. As expected with an emerging new tech-
nology, this meta- analysis has captured results from studies using 
Table 3 Categorisation of diagnostic discordances
Discordance groups (organs involved) Percentage
A Nuclear features, dysplasia, malignancy18 23 25 27 31 32 42–47 49 57%
1. Identification and grading of epithelial dysplasia (colon, stomach, larynx, cervix, lung, penile, bladder and skin)
2. Identification and grading of nuclear atypia (thyroid, uterus, breast and skin)
3. Grading of malignancy (prostate, breast and endocrine pancreas)
4. Missed/over- diagnosis of malignancy (lymph node, thyroid, colon, salivary gland, breast, urethra, testis, lung, prostate, adrenal and kidney)
5. Subtyping of malignancy
B Identification of small objects23–27 31 40 43 48 49 16%
1. Identification of microorganisms, eg, Mycobacteria, fungi, Helicobacter pylori, Gram- positive cocci (stomach, oral mucosa, small bowel and skin)
2. Identification of mitotic figures (breast and skin)
3. Identification of inflammatory lesions and cells (oesophagus, colon, duodenum, stomach, cervix, oral mucosa and brain)
4. Identification of granulomata (colon)
5. Detection of metastasis or micro- metastasis (skin, ovary and breast)
6. Identification of Weddellite calcification (breast)
7. Recognition of small area with diagnostic features (endometrium)
C Challenging diagnoses20 25 26 31 32 41 43–49 26%
1. Melanocytic lesions (skin)
2. Atypical breast lesions (eg, B3 lesions)
3. Identification of amyloid and mucin (skin)
4. Focally invasive/malignant lesion (stomach, colon, tongue, breast, thyroid and bladder)
5. Transplant biopsies (kidney)
D Miscellaneous23 25 40 1%
1. Identification of ischaemia, necrosis or granulation tissue (colon)
2. Intestinal metaplasia (stomach)
3. Identification of ganglions (eg, Hirschsprung)
Figure 7 Distribution of four groups of discordances across the 
specialties involved.
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differing technologies. Despite improvements in image quality, the 
more recent equipment can provide there was no difference in 
discrepancy rates over the course of these studies. This most likely 
indicates that even the earlier DP studies used equipment capable of 
delivering a diagnostic tool equivalent to LM.
Although this review provides strong and consistent evidence 
of the equivalent performance of DP in comparison with LM, 
it also highlights certain areas where the evidence is still weak. 
First, the majority of the studies provide no evidence base for 
sample size and no power calculation, which prevent a statistical 
measurement of inferiority. Second, the intra- observer and inter- 
observer variability on existing LM platform is unknown, so it 
is not possible to calculate the number of discrepancies actually 
related to viewing modality.
CONCLUSION
Although the barriers to wider adoption of DP have been multi-
factorial, limited evidence of reliability has been a significant 
contributor. The COVID-19 pandemic acted as a catalyst to 
change working practice across the health sector.37 The flexi-
bility provided by digitising the workflow is fundamental to 
these changes, and DP is a key step to enabling this to happen in 
cellular pathology.38 39 The demand for widespread adoption of 
DP is growing further as a result.
The results of this meta- analysis represent significant evidence 
to indicate the equivalent performance of DP for routine diag-
nosis. Furthermore, the categorisation of diagnostic discordances 
highlights a number of potential limitations, where alternative 
solutions may be needed. The findings also indicate how the 
enrichment of sample selection in future studies may improve 
the evidence base further.
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Take home messages
 ► The results of this meta- analysis provide the strongest 
evidence to date that DP is a viable alternative to LM 
for routine practice and, given the multiple additional 
advantages it offers, can be expected to replace the LM as 
the main tool for diagnostic histopathology.
 ► Evidence- based widespread adoption of DP is a key step to 
enable workflow delivery in the current pandemic situation.
 ► For the first time the areas of diagnostic discrepancies have 
been synthesised from the available data which is essential in 
enabling pathologists to understand the limitations of DP and 
be able to adapt to its use in their own practice safely, and 
guide industry to develop more solutions.
Table 4 QUADAS 2—assessment of risk of bias and applicability concerns across 25 studies
Study ID
Risk of bias Applicability concerns
Case selection Index test Reference standard Flow and timing Case selection Index test Reference standard
Al- Janabi et al40 Low Low Low Low Low Low Low
Bauer et al43 Low Low Low High Low Low Low
Campbell et al18 Unclear Low Low Low Low Low Low
Al- Janabi et al41 Low Low Low Low Low Low Low
Brunelli et al28 Unclear Low Low Low Low High Low
Houghton et al30 High Low Low Low Low Low Low
Reyes et al20 Low Low Low Low Low Unclear Unclear
Bauer and Slaw3 Low Low Low Low Low Low Low
Ordi et al27 Low High High High Low Low Low
Bucks et al (1)23 High Low Low Low Low Low Low
Bucks et al (2)23 High Unclear High Low Low Unclear Unclear
Arnold et al24 Low Unclear Low Low Low Unclear Low
Loughrey et al29 High Low Low Low Low Low low
Thrall et al26 Low Low Low Low Low Low Low
Shah et al46 Low Low Low Low Low Low low
Snead et al25 Low Low Low Low Low Low Low
Saco et al19 Low Low Low Low Low Low Low
Kent et al45 Low Low Low Low Low Low Low
Tabata et al31 High Low Low Low Low Low Low
Araújo et al42 High Low Low Low Low Low Low
Lee et al48 Low High Low High Low Unclear Unclear
Villa et al47 Low Low Low Low Low Low Low
Mukhopadhyay et al32 High Low Low Low Low Low Low
Williams et al6 Low Unclear Low High Low Unclear Low
Hanna et al44 Low Low Low Low Low Low Low
QUADAS2, Quality Assessment of Diagnostic Accuracy Studies.
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